Johnson & Johnson
JNJ
NYSE165.06
Johnson & Johnson
NYSE:JNJ
RECENT
PRICE
165.06
P/E
RATIO
24.12
(PEG:0.58)
P/E RATIO
RELATIVE
TO S&P
1.20
DIV
YLD
2.54%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.61 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 09/22:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2010
2011
2012
2012
2013
2014
2016
2017
2017
2018
2019
2021
2022
TTM
Fiscal year
18.14
3.76
3.92
1.45
21.20
3.67
4.14
1.62
22.67
4.61
4.23
1.79
22.43
4.44
5.15
1.93
22.49
4.87
5.11
2.12
23.87
3.55
4.19
2.26
24.19
3.91
4.49
2.38
25.28
4.90
4.90
2.58
26.71
5.86
5.30
2.79
25.43
5.59
5.74
2.97
26.56
6.11
5.74
3.19
28.50
0.48
6.63
3.33
30.64
5.75
6.96
3.57
31.17
5.74
7.57
3.77
31.37
5.59
7.67
3.98
35.63
7.93
7.51
4.19
45.25
8.94
7.58
4.31
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.93
13.38
1.15
15.03
1.09
15.12
0.86
18.33
0.87
20.66
1.06
20.95
1.06
23.33
1.27
26.25
1.33
25.06
1.26
25.82
1.19
26.02
1.22
22.43
1.38
22.44
1.33
22.59
1.27
24.04
1.39
28.12
1.38
28.07
CAPEX per share
Book Value per share
2,940
2,882
2,812
2,760
2,738
2,724
2,778
2,821
2,783
2,755
2,707
2,683
2,662
2,633
2,633
2,632
2,630
Comm.Shares outs.(m)
16.5
0.9
2.3%
17.4
1.0
2.5%
14.0
0.7
2.8%
13.9
0.7
3.1%
13.0
0.8
3.3%
18.9
1.3
3.4%
17.2
1.2
3.6%
17.4
1.0
3.0%
17.1
0.9
2.8%
20.3
0.9
2.6%
21.2
0.9
2.5%
267.4
11.3
2.6%
23.1
0.9
2.7%
23.5
1.0
2.8%
29.6
1.0
2.4%
21.6
1.1
2.4%
24.1
1.2
2.5%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (3/7/22 | )
Total liabilities
$101,367 m.
Total assets
$177,724 m.
Long-term debt
$28,292 m.
Cash and equiv.
$10,983 m.
Goodwill $34,166 m.
Retained earnings $126,216 m.
Common stock 2,630 m. shares
Market Capitalisation
$435,655 m. (as of 27/9/22)
65,030
24.8%
67,224
25.3%
71,312
26.6%
74,331
28.4%
70,074
26.1%
71,890
29.4%
76,450
25.0%
81,581
26.0%
82,059
25.6%
82,584
24.1%
93,775
26.2%
119,014
25.7%
Revenue (m)
Operating margin
3,158
9,672
3,666
10,853
4,104
13,831
3,895
16,323
3,746
15,409
3,754
16,540
5,642
1,300
6,929
15,297
7,009
15,119
7,231
14,714
7,390
20,878
5,401
23,515
Depreciation (m)
Net profit (m)
21.8%
14.9%
23.7%
16.1%
10.6%
19.4%
20.6%
22.0%
19.7%
22.0%
16.5%
23.0%
92.6%
1.7%
15.0%
18.8%
12.7%
18.4%
10.8%
17.8%
8.3%
22.3%
8.5%
19.4%
Income tax rate
Net profit margin
31,505
12,969
57,080
21,854
11,489
64,826
30,732
13,328
74,053
34,226
15,122
69,752
32,463
12,857
71,150
38,745
22,442
70,418
12,551
30,675
60,160
14,803
27,684
59,752
9,310
26,494
59,471
8,744
32,635
63,278
15,753
29,985
74,023
19,026
28,292
76,357
Working capital (m)
Long-term debt (m)
Equity (m)
11.1%
11.4%
16.9%
11.5%
12.1%
16.7%
13.3%
12.0%
18.7%
15.8%
16.1%
23.4%
15.0%
14.8%
21.7%
14.9%
14.5%
23.5%
1.1%
11.8%
2.2%
13.3%
12.4%
25.6%
12.6%
11.2%
25.4%
11.2%
9.5%
23.3%
15.4%
12.6%
28.2%
18.2%
14.8%
30.8%
ROIC
Return on capital
Return on equity
Working Capital
2019
2021
2022
Cash assets
19,287
27,771
28,273
Receivables
14,481
13,576
15,283
Inventory
9,020
9,344
10,387
Other
2,486
3,132
3,701
Current assets
45,274
51,237
60,979
Acc. Payable
8,544
9,505
11,055
Debt due
1,202
2,631
3,766
Other
26,218
30,357
30,405
Current liab.
35,964
42,493
45,226
36.4%
76.1%
39.1%
156.7%
47.3%
78.3%
52.4%
100.9%
47.0%
85.1%
47.9%
113.2%
(587.9)%
86.1%
37.9%
82.9%
34.4%
83.7%
28.8%
67.9%
47.2%
73.3%
38.3%
76.6%
Plowback ratio
Div.&Repurch. to FCF
Johnson & Johnson (US) started trading on September 1, 1944 (cik: 0000200406), operates in the Healthcare sector (Drug Manufacturers—General industry), has 141,700 full-time employees, and is led by Mr. Alex Gorsky. Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
5.37%
3.89%
Cash flow
2.74%
5.38%
Earnings
278.69%
118.87%
Dividends
5.39%
5.86%
Book value
5.56%
1.90%
Insider trading
Type
Shares
Date
Hewson Marillyn A
Award
260
09/06/22
Washington A. Eugene
Award
379
09/06/22
Weinberger Mark A
Award
261
09/06/22
Wengel Kathryn E
Exempt
40,000
06/10/22
Wengel Kathryn E
Sale
33,126
06/10/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2021
20,691
18,336
21,082
22,475
82,584
2022
22,321
23,312
23,338
24,804
93,775
2023
23,426
- -
- -
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2021
2.20
1.38
1.35
0.66
5.59
2022
2.35
2.39
1.39
1.80
7.93
2023
1.96
- -
- -
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2021
0.95
1.01
1.01
1.01
3.98
2022
1.01
1.06
1.06
1.06
4.19
2023
1.06
- -
- -
- -
- -
09/16/2022
Jurist Noted for Bankruptcy Expertise Will Weigh J&J Talc Appeal
The Wall Street Journal - Read more...
07/19/2022
Johnson & Johnson Trims Full-Year Guidance on Stronger Dollar
The Wall Street Journal - Read more...
06/06/2022
J&J Plans to End Covid-19 Vaccine Deal With Emergent BioSolutions
The Wall Street Journal - Read more...
05/24/2022
Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
The Wall Street Journal - Read more...
05/11/2022
J&J Names Executives of Tylenol, Band-Aid Company
The Wall Street Journal - Read more...
05/05/2022
FDA Limits Use of Johnson & Johnson’s Covid-19 Vaccine
The Wall Street Journal - Read more...
05/04/2022
J&J Sues Drug-Benefit Middleman Over Drug-Cost Assistance Program
The Wall Street Journal - Read more...
04/26/2022
Johnson & Johnson Sues Alleged HIV-Drug Counterfeiters
The Wall Street Journal - Read more...
04/19/2022
Johnson & Johnson Backs Off Covid Vaccine Sales Guidance
The Wall Street Journal - Read more...
04/18/2022
J&J Settles With West Virginia in Opioid Suit for $99 Million
The Wall Street Journal - Read more...
03/30/2022
Justice Department Probes Alleged Sales of Counterfeit HIV Drugs
The Wall Street Journal - Read more...
02/28/2022
FDA Approves Cell-Based Therapy for Blood Cancer Discovered in China
The Wall Street Journal - Read more...
02/25/2022
Johnson & Johnson, Drug Distributors Agree to Opioid Settlement With States
The Wall Street Journal - Read more...
02/25/2022
Judge Backs J&J’s Talc Bankruptcy, Keeping Cancer Lawsuits Frozen
The Wall Street Journal - Read more...
02/02/2022
Native American Tribes Reach $590 Million Opioid Settlement
The Wall Street Journal - Read more...
01/25/2022
Johnson & Johnson Posts Higher Quarterly Sales Despite Some Pandemic-Related Pains
The Wall Street Journal - Read more...
01/25/2022
AMC, IBM, Microsoft, GE: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/17/2021
Rivian, FedEx, Cerner, Oracle: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/17/2021
CDC Recommends Pfizer, Moderna Covid-19 Vaccines Over J&J’s
The Wall Street Journal - Read more...
12/06/2021
J&J Prepares to Untangle Finances Ahead of Planned Split
The Wall Street Journal - Read more...
11/29/2021
Omicron Variant Has Covid-19 Vaccine Makers Preparing for Worst Case
The Wall Street Journal - Read more...
11/29/2021
Moderna, Coinbase, Occidental, Royal Caribbean: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/26/2021
J&J Covid-19 Vaccine Recipients Shift to Other Boosters
The Wall Street Journal - Read more...
11/21/2021
Most Vulnerable More at Risk of Breakthrough Hospitalization
The Wall Street Journal - Read more...
11/12/2021
What to Know About Johnson & Johnson’s Breakup
The Wall Street Journal - Read more...
11/12/2021
Johnson & Johnson Breakup Is No Clean Sweep
The Wall Street Journal - Read more...
11/12/2021
Johnson & Johnson to Split Consumer From Pharmaceutical, Medical-Device Businesses, Creating Two Companies
The Wall Street Journal - Read more...
11/12/2021
Rivian Automotive Stock Price: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
11/12/2021
J&J Split Sees Band-Aid, Tylenol Go Their Own Way
The Wall Street Journal - Read more...
11/12/2021
How Bankruptcy Could Help Johnson & Johnson Corral Vast Talc Litigation
The Wall Street Journal - Read more...
11/11/2021
J&J Talc Bankruptcy Case Moved to New Jersey From North Carolina
The Wall Street Journal - Read more...
11/09/2021
Johnson & Johnson Opioid Verdict Overturned by Oklahoma Supreme Court
The Wall Street Journal - Read more...
11/03/2021
Vaccine Boosters’ Mix-and-Match Efficacy
The Wall Street Journal - Read more...
11/02/2021
Opioid Manufacturers Score Win in California Lawsuit
The Wall Street Journal - Read more...
10/22/2021
Moderna and J&J Covid-19 Booster Shots Backed by CDC
The Wall Street Journal - Read more...
10/20/2021
FDA Authorizes Covid-19 Vaccine Boosters From Moderna, J&J
The Wall Street Journal - Read more...
10/19/2021
Johnson & Johnson’s Sales Climb Across Divisions
The Wall Street Journal - Read more...
10/19/2021
Johnson & Johnson’s Stock Deserves a Booster
The Wall Street Journal - Read more...
10/19/2021
Dover, Procter & Gamble, Travelers, Netflix: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/18/2021
FDA Nears Approval for Mixing Covid-19 Booster Shots
The Wall Street Journal - Read more...
10/18/2021
Zillow, State Street, Valneva, Upstart: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
10/15/2021
J&J Covid-19 Booster Shot Endorsed by FDA Advisers
The Wall Street Journal - Read more...
10/13/2021
J&J Booster Dose Bolsters Protection Against Covid-19, FDA Says
The Wall Street Journal - Read more...
10/12/2021
Johnson & Johnson’s Top Scientist to Depart
The Wall Street Journal - Read more...
10/05/2021
Johnson & Johnson Asks FDA to Authorize Covid-19 Booster
The Wall Street Journal - Read more...
09/17/2021
Moderna’s Covid-19 Shot Best Prevents Hospitalization, Study Indicates
The Wall Street Journal - Read more...
09/04/2021
Covid-19 Vaccine Booster Launch Could Be Delayed for Many
The Wall Street Journal - Read more...
08/31/2021
Zoom Video, AMC, CrowdStrike: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
08/28/2021
Covid-19 Vaccine Efficacy: What Do the Numbers Really Mean?
The Wall Street Journal - Read more...
08/25/2021
J&J Says Covid-19 Booster Prompts Strong Immune Response
The Wall Street Journal - Read more...
08/17/2021
As Delta Surges, Covid-19 Breakthrough Cases Remain Uncommon
The Wall Street Journal - Read more...
08/12/2021
Vaccine Scammers Target Authorities in Dozens of Countries
The Wall Street Journal - Read more...
08/12/2021
FDA Moving Toward Decision Authorizing Booster Shot for Immunocompromised
The Wall Street Journal - Read more...
08/06/2021
J&J Vaccine Highly Effective Against Delta Variant in South African Trial
The Wall Street Journal - Read more...
08/03/2021
U.S. Has Shared 110 Million Covid-19 Vaccine Doses Overseas
The Wall Street Journal - Read more...
07/29/2021
J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Plant
The Wall Street Journal - Read more...
07/21/2021
Johnson & Johnson Posts Higher Quarterly Profit
The Wall Street Journal - Read more...
07/21/2021
Coca-Cola, Johnson & Johnson, Chipotle: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
07/20/2021
$26 Billion Opioid Settlement Expected This Week
The Wall Street Journal - Read more...
07/15/2021
Blackstone, AIG, NortonLifeLock, Morgan Stanley: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
07/12/2021
FDA Warns J&J Covid-19 Vaccine Raises Risk of Rare Neurological Condition
The Wall Street Journal - Read more...
07/02/2021
J&J Vaccine Shows Promise Protecting Against Delta Variant
The Wall Street Journal - Read more...
06/26/2021
Johnson & Johnson Settles New York Opioid Case for $230 Million
The Wall Street Journal - Read more...
06/16/2021
Roblox, Oracle, Greenland Tech, Kindred Biosciences: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
06/11/2021
FDA Approves Export of Covid-19 Vaccine Doses From Troubled Plant
The Wall Street Journal - Read more...
06/08/2021
Millions of J&J Covid-19 Vaccines Are at Risk of Expiring in June
The Wall Street Journal - Read more...
06/01/2021
Supreme Court Won’t Consider Johnson & Johnson Challenge to Baby Powder Judgment
The Wall Street Journal - Read more...
05/28/2021
FDA, J&J Near Deal for Vaccine Production at Baltimore Plant
The Wall Street Journal - Read more...
05/09/2021
J&J Vaccine Pause Stoked Hesitancy That Threatens Covid-19 Vaccination Drive
The Wall Street Journal - Read more...
05/07/2021
AstraZeneca Weighs Seeking Full U.S. Approval for Covid Shot, Skipping Emergency-Use Application
The Wall Street Journal - Read more...
05/06/2021
U.S. Backs Waiver of Intellectual Property Protection for Covid-19 Vaccines
The Wall Street Journal - Read more...
05/02/2021
Opioid-Crisis Lawsuit Heads for Trial in West Virginia
The Wall Street Journal - Read more...
04/26/2021
W.R. Grace, AMC, Ocugen, Carnival: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
04/25/2021
Vaccination Sites Restart J&J’s Covid-19 Vaccinations
The Wall Street Journal - Read more...
04/24/2021
U.S. Lifts Pause on J&J’s Covid Vaccine
The Wall Street Journal - Read more...
04/24/2021
Do J&J and AstraZeneca Vaccines Cause Blood Clots, and What Are the Symptoms?
The Wall Street Journal - Read more...
04/21/2021
FDA Finds Poor Conditions at Contractor’s Plant Making J&J Vaccine
The Wall Street Journal - Read more...
04/20/2021
J&J Vaccine Benefits Outweigh Risks, EU Agency Says, as U.S. Cases Rise
The Wall Street Journal - Read more...
04/20/2021
J&J’s Covid-19 Vaccine Adds $100 Million to Quarterly Sales
The Wall Street Journal - Read more...
04/20/2021
Kansas City Southern, IBM, United Airlines: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
04/18/2021
J&J Vaccine Pause Driven by Risk of Mistreating Clots
The Wall Street Journal - Read more...